Symposium

Cannabis Health Symposium: London

The UK is forecasted to have up to 130k patients this year. London will feature evidence-based education for UK clinicians, prescribers and the wider medical cannabis community.

Healthcare professional?

Concession tickets

Concession tickets are for healthcare professionals and are available by application. Apply below — once we’ve verified your details we’ll email you a booking link.

The Houses of Parliament and Elizabeth Tower (Big Ben), in the Cannabis Health mint duotone.
Date
26 November 2026
Time
08:30 – 17:00
Location
Conway Hall, London, United Kingdom
Who it’s for
Healthcare professionals & clinicians · Industry professionals · Patient advocates
CPD
CPD certified — Accredited by The CPD Certification Service
Included
12 months' free MCCS membership — worth up to £120

Final Release£284.09incl. fees

Book tickets

Enter your email to continue to checkout for Cannabis Health Symposium: London.

HCP concession£100for healthcare professionals

Concession tickets

Concession tickets are for healthcare professionals and are available by application. Apply below — once we’ve verified your details we’ll email you a booking link.

Every ticket: CPD certified · 12 months' free MCCS membership, worth up to £120

The Cannabis Health Symposium returns to London for a full day of evidence-led education across policy, regulation, access and clinical practice — bringing together healthcare professionals, industry and patient advocates.

Programme

26 November 2026 · 08:30 – 17:00 · 22 sessions, including 4 panel debates

Programme subject to change — session times, titles and speakers may be updated.

  1. 08:30Doors open — registration & networking coffee
  2. 09:20

    Opening remarks & welcome

    • Sarah Sinclair · Editor, Cannabis Health
  3. 09:30

    Presentation

    Curaleaf Education Platform: Free Education for Prescribers

    The Symposium's headline partner, Curaleaf, introduces its education platform: free education for prescribers.

Morning session: Policy, regulation & access

  1. 10:00

    Fireside chat

    Making the UK a Cannabinoid Science Leader: A Fireside with Professor Trevor Jones

    • Trevor Jones · Co-Chair, UK Cannabinoid R&D Group
    • Sarah Sinclair · Editor, Cannabis Health

    Eight years after cannabis-based medicines were rescheduled in the UK, the research base has barely moved. Only three cannabis-based medicines have been approved for prescription, and the vast majority of products prescribed are unlicensed, supplied via the specials route and administered by private clinics. Prescribers are asked to make decisions without the trial data they would expect for any other therapeutic class, while the researchers who could generate that data face a regulatory framework that still treats most of the plant's compounds as having no medicinal value. The result is a field where clinical demand has run far ahead of the evidence, and where the UK risks ceding scientific leadership to countries that have made research easier.

    Read more

    Professor Trevor Jones has spent a career at the intersection of pharmaceutical R&D and national policy, and as co-chair of the Cannabinoid Research and Development Group alongside George Freeman MP, he is leading the effort to change that picture. The group set out to produce the country's first comprehensive strategy for cannabinoid R&D, integrating universities, research institutions, investors, businesses and the NHS. In this conversation he sets out the CRDG's priorities, from reform of Schedule 1 licensing and clearer MHRA guidance to the case for targeted research exemptions, and explains what a functioning pathway from lab to licensed medicine would actually require. For the prescribers and policymakers in the room, it is a rare chance to hear the argument directly from the person making it to government.

    This fireside discusses why Schedule 1 remains the single biggest barrier to UK cannabinoid research, what practical changes to Home Office licensing and MHRA guidance would unlock trials fastest, how research exemptions could work without weakening controls, and what role clinicians can play in building the evidence base the field needs.

  2. 10:20

    Panel discussion

    Building a safe, effective and compliant medical cannabis service

    • David Tang · CEO & Founder, CannPrescribe
    • Adam Cole · Chief Technology & Program Strategist, Goji Technology Systems Inc
    • Nitin Makadia · Director of Clinical Service Development, The Digital Health Assurance Company

    As the sector continues to mature, robust governance and regulatory compliance remain essential for clinics providing cannabis-based medicines. This practical panel will explore the systems, processes and quality standards required to meet Care Quality Commission expectations, and how the same process works in other key markets outside the UK.

    Read more

    Attendees will gain insight into common challenges, lessons learned from inspections, and practical strategies for achieving and maintaining good or outstanding ratings. The session is designed for clinic operators, medical directors and governance leads seeking to strengthen their compliance frameworks and improve patient safety.

  3. 11:00

    Presentation

    Medical cannabis in the workplace: safety, compliance and employee rights

    • Professor Kim Wolff · Director of King's Forensics, King's College London

    As the number of prescribed medical cannabis patients continues to grow, employers and occupational health professionals are increasingly faced with complex questions around workplace safety, drug testing, fitness for work and reasonable adjustments. This session will explore the legal and practical considerations surrounding medical cannabis in employment settings, including the challenges faced by patients working in safety-critical roles — towards fair, evidence-based workplace policies.

  4. 11:30

    Presentation

    Medical cannabis police guidance: understanding rights and responsibilities

    • Richard List QPM · National Secretary and CDLO, Association of Police Controlled Drug Liaison Officers

    Despite legalisation, many medical cannabis patients continue to experience confusion and inconsistency when interacting with law enforcement. This session will present the latest police guidance for medical cannabis patients, helping clinicians, patients and healthcare providers better understand the practical implications of the law and how it is being applied across the UK.

  5. 12:00

    Presentation

    Setting the Standard: How Harmonisation Turns CBMs Into Trusted Care

    • Ana Serrato · Chair, Cannabis Human Health Subcommittee (D37.11); Chairwoman, EUMCA, ASTM International

    Across Europe, early access programmes for cannabis-based medicines run under fragmented, country-specific rules, each with its own quality expectations, evidence requirements and pathway to patients. That fragmentation leaves manufacturers, regulators and healthcare professionals without a shared language, making it hard to guarantee that patients receive consistently high-quality, safe products wherever they are treated.

    Read more

    That is the gap ASTM D37.11: Human Health is built to close, covering product quality, health evidence and responsible use in one framework. Closing it gives manufacturers one consistent technical reference, healthcare professionals reliable evidence to guide prescribing, patients assurance of quality and safety, regulators a harmonised benchmark, and investors the predictability needed for cross-border trade. Trusted cannabinoid-based care will not come from national regulation alone. It requires one shared standard, built for the full journey from product to patient.

  6. 12:20

    Presentation

    Headline partner presentation — Curaleaf Laboratories

  7. 12:40

    Presentation

    Real-world use of cannabinoid-based medicines in routine clinical practice: treatment patterns and physician-reported outcomes

    • Dr Julian Haist · Medical Affairs Representative, Tilray Medical

    Cannabinoid-based medicines are increasingly being used in patients with complex and often chronic conditions. Drawing on 106 documented cases from the Physicians Experience Platform (PEP), this analysis examines treatment patterns, dosing, tolerability and physician-reported outcomes in routine clinical practice. The findings offer practical real-world insights into the management of patients who have frequently received extensive prior treatments.

  8. 13:00Lunch & networking

Afternoon session: Science and clinical practice

  1. 14:00

    Panel discussion

    Managing risk and maximising benefit in mental health care

    • Edward Chesney · Clinical Lecturer, King's College London
    • Dr Iain Pryde · Consultant Psychiatrist, Tilray Medical x Lyphe Clinic
    • Kate Thorpe · Executive Director, Medical Cannabis Clinicians Society (MCCS)

    Mental health remains one of the most discussed and debated areas of medical cannabis practice. This session will examine the current evidence for cannabis-based medicines in psychiatric conditions, while addressing concerns around safety, dependency, psychosis risk and patient selection. Leading psychiatrists and clinicians will discuss prescribing considerations, risk mitigation strategies and the role of cannabis-based medicines within wider mental health treatment pathways. The session will provide practical guidance for clinicians navigating this complex and evolving area of practice.

  2. 14:40

    Presentation

    Cannabis for Neurological Disorders and Neurodiversity: Fact or Fiction?

    Interest in the use of cannabis-based medicines for neurodevelopmental conditions continues to grow among clinicians, patients and families. This panel discussion will examine the current evidence surrounding the use of CBMPs in Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder, while exploring gaps in conventional treatment options and emerging understanding of the endocannabinoid system in neurodivergent populations. Combining clinical expertise, research perspectives and lived experience, the session will provide a balanced discussion of the opportunities, challenges and unanswered questions in this rapidly evolving area.

  3. 15:00

    Presentation

    RCT vs RWE: is it time to look beyond the placebo-controlled trial?

    • Professor David Nutt · Professor of Neuropsychopharmacology, Imperial College London, Drug Science

    For the last 50 years, randomised controlled trials (RCTs) have been considered the 'gold standard' in research measuring the safety and efficacy of new drugs. But there are known limitations of these types of studies, particularly in cannabinoid medicine, and some argue we should give greater weight to other types of evidence like real-world data when determining whether treatments are safe and effective. This session will explore whether it's time for the scientific community to look beyond the double-blind placebo-controlled trial.

  4. 15:30

    Presentation

    Addressing unmet needs in women's health

    • Dr Grace Blest-Hopley · Founder & Researcher, Hystelica

    Women are increasingly seeking cannabis-based medicines to manage a range of conditions that are often poorly served by conventional treatment options. This session will explore the use of medical cannabis across menopause, endometriosis, PMDD, chronic pelvic pain and related disorders — examining the current evidence, clinical experience and future research priorities, and how healthcare providers can better support women seeking alternative treatment approaches.

  5. 15:50

    Panel discussion

    Medical Cannabis and Pain Treatment: What Real World Evidence Tells Us

    • Dr Simon Tordoff · Consultant in Pain Management, CB1 Medical
    • Garvin Hirt · Co-Founder & CEO, Copeia
    • Nabila Chaudhri · Medical Director, Montu UK / Alternaleaf
    • Dr Zack Bellman · Lead Researcher, CRDG UK; Founder, Cannabinoid Pipeline Insights

    Chronic pain remains the most common reason patients seek a medical cannabis prescription, yet the evidence base is still catching up with clinical demand. This panel brings together registry data, prescribing experience and independent clinical scrutiny to ask what the real-world evidence actually shows, and where it falls short.

    Read more

    Drawing on UK Medical Cannabis Registry outcomes, frontline prescribing experience and the perspective of the Advisory Council on the Misuse of Drugs, speakers will examine THC:CBD response patterns, opioid-sparing potential, and the data gaps still standing between promising patient outcomes and broader clinical or reimbursement acceptance. Rather than another advocacy panel, this session is built to stress-test the evidence itself: what counts as robust data, what remains anecdotal, and what needs to happen next for medical cannabis to earn its place in mainstream pain management.

  6. 16:20

    Panel discussion

    Patient Voices: Real-World Experiences of Prescribed Cannabis-Based Medicines

    • Julie Durrans · Prescribed patient & patient advocate
    • Carola Pérez · Director, We, The Patients
    • Nicola Stevenson · Prescribed patient, advocate & industry consultant, The M-C Fairy
    • Liam O'Dowd · Editor & Co-Founder, leafie

    Cannabis is a very personalised treatment and good communication between prescribers and their patients is crucial. Listening to the patients' perspective provides clinicians with a vital source of insight into the real-world impact of these medicines, which can help inform future prescribing decisions.

    Read more

    This patient panel will give healthcare and industry professionals a unique opportunity to hear directly from patients about their lived experiences with cannabis-based medicines, from navigating access to managing day-to-day treatment. It will explore how prescribers and the wider care team can work effectively with patients to build trust, meet their needs and deliver person-centred care.

  7. 17:00Close
  8. 17:00Post-conference drinks — The Enterprise, 38 Red Lion Street, Holborn (until 19:00)

Workshop stage — runs alongside the main programme

  1. 10:00

    Roundtable

    Patients Roundtable: Medical Cannabis Patient Voices

    This roundtable brings together patient-led organisations — We, The Patients, Patients First UK, PatientsCann UK and United Patients Alliance — who speak for people across the UK and Europe who use or are seeking medical cannabis, including many living with chronic pain, neurological conditions and other long-term illness.

    Read more

    It is a collaborative, patient-led discussion in which the organisations share what their members tell them about access and affordability, product quality and consistency, rights in daily life such as work, travel and driving, stigma, and the quality of information available to patients. Industry representatives are invited to listen in rather than present or pitch, so that manufacturers, prescribers, pharmacies and others gain a first-hand view of what patients need and can respond to it in their own work.

  2. 10:50

    Interactive workshop

    Patient Discrimination: Understanding Rights, Managing Incidents and Supporting Patients

    • Alex Fraser · Founder & Managing Director, Patient Protect

    An interactive training workshop for medical cannabis prescribers and healthcare professionals. While medical cannabis has been legally prescribed in the UK since 2018, patients continue to encounter stigma, misunderstanding and discrimination in their everyday lives. Led by Alex Fraser, founder of Patient Protect, this workshop will equip prescribers with the knowledge and confidence to better support patients facing challenges relating to their prescribed medication.

    Read more

    Drawing on real-world cases reported to Patient Protect, the session will explore common areas of discrimination, including policing and driving, employment, housing and child custody. Participants will examine relevant legal protections, how incidents typically unfold, and the practical steps clinicians and clinics can take to support affected patients. Using case studies, patient reporting data and interactive discussion, it will explore how healthcare professionals can help prevent misunderstandings, respond effectively when problems arise, and empower patients to exercise their rights with confidence.

    The session will also consider the wider role of prescribers and the medical cannabis industry in tackling stigma, improving public understanding and promoting the normalisation of prescribed cannabis medicines, and concludes with an introduction to Patient Protect's support services and resources for patients and prescribing clinics.

  3. 11:20

    Presentation

    Nurses in Cannabis Care: The Case for Expanding Nursing Roles in the UK Sector

    • Adam Windish · CEO, British Cannabis; Education, Awareness & Standards Pillar Lead, Cannabis Industry Council

    The UK medical cannabis sector has expanded rapidly since cannabis-based products for medicinal use (CBPMs) were legalised in 2018, yet nursing involvement remains underdeveloped. The sector is largely private and telemedicine-led, while the pool of specialist prescribers who can initiate unlicensed CBPM treatment remains limited.

    Read more

    Adam Windish, Awareness, Standards & Education Pillar Lead for the Cannabis Industry Council, presents the CIC's newest educational report, produced in partnership with Ariana Ayu, RN, MSc, founder of the CannyNurse Certificate Program. "Nurses in Cannabis Care" argues for a structured expansion of nursing roles, supported by specialist education, clear governance and defined escalation pathways.

  4. 11:50

    Presentation

    Patient Safety and the Illicit Market: What Prescribers Need to Know

    • Shanna Marrinan · Director of Research, 4C Labs

    Medical cannabis has an unusually strong safety profile, and even in illicit markets, serious harm is rare. But rare is not the same as absent, and where risk does show up, it rarely comes from the cannabis itself. This session presents new analysis of UK drug-checking data from WEDINOS (Welsh Emerging Drugs & Identification of Novel Substances), examining 578 cannabis-intent samples submitted over an 18-month period through anonymous postal testing and police and prison seizures. Using LC-QTOF chemical analysis capable of detecting novel psychoactive substances, the research found that nearly half of all samples (48.79%) were compromised: containing substances with no natural place in cannabis. Most strikingly, 188 samples contained no cannabinoids at all, having been fully substituted with an active adulterant, while a further 37 combined cannabis with an added psychoactive compound.

    Read more

    The scale of synthetic cannabinoid receptor agonist contamination is a key finding, present in over a quarter of all samples tested, with MDMB-4en-PINACA alone detected in one in five. For clinicians and policymakers, this raises a pointed question: how much of the harm attributed to "cannabis" in unregulated settings is actually harm from something else entirely, deliberately added to boost perceived potency or appeal. The session will walk through the data, unpack the likely motivations and consequences behind this kind of adulteration, and consider what it means for the case for a fully regulated, GMP-certified medical cannabis supply chain, where this category of risk is largely designed out.

    This session covers: how common is adulteration really, what compounds are showing up and why, what these findings suggest about supply chain risk versus cannabis risk itself, and how regulation and GMP standards change the picture.

  5. 12:20

    Workshop

    Prescription to Pharmacy: Inside Greece's Medical Cannabis Framework

    • Panos Papatheologou · Co-Founder & CEO, ReliefTime

    Greece was one of Europe's earliest movers on medical cannabis, legalising it in 2017, yet patients waited almost seven years for the first legal prescriptions to be filled. What emerged is one of the continent's most tightly defined models. Every product must be authorised as a finished pharmaceutical by the national regulator, prescriptions flow through the country's national e-prescribing system and can be filled at any pharmacy, and patients pay the full cost with no reimbursement. A new generation of telemedicine services connecting patients with Greek-licensed doctors by video has entered that structure.

    Read more

    In this session, we'll learn how that infrastructure works day to day, from eligibility and consultation through to the pharmacy counter. This workshop explores how Greece's pharmaceutical-grade product requirements shape patient access, how national e-prescribing compares with the UK's private clinic and pharmacy pathway, what telemedicine looks like under each framework, and which elements of the Greek model could realistically translate to the UK.

  6. 14:00

    Workshop

    Beyond Pharmacology: How Social Science Can Improve Medical Cannabis Patient Outcomes

    • Dr Anna Waldstein · Senior Lecturer in Medical Anthropology, University of Kent

    As medical cannabis becomes increasingly integrated into healthcare, attention is often focused on clinical evidence, prescribing practice and pharmacology. However, patient outcomes are influenced by more than the therapeutic properties of cannabis-based medicines alone. Social, cultural and behavioural factors play a significant role in shaping treatment engagement, adherence, patient experience and, ultimately, clinical results.

    Read more

    This session explores how insights from sociology and anthropology can enhance medical cannabis care. Social science research on cannabis spans diverse areas, including therapeutic cannabis traditions, patient experiences, health behaviours, stigma, identity, ethnicity and the social determinants of health. These perspectives provide valuable tools for understanding how patients make sense of their illness, develop expectations of treatment, and navigate decisions about cannabis use within their social and cultural environments.

    Drawing on concepts such as explanatory models, illness narratives and structural violence, the session will demonstrate how social science frameworks can be applied in routine clinical practice. Through real-world examples and case studies, participants will learn why patients with similar conditions and prescriptions often report very different experiences and outcomes, and how clinicians can better identify and address non-pharmacological barriers to successful treatment.

    Designed for clinicians involved in medical cannabis prescribing and patient management, this session translates social science research into actionable strategies that can be applied immediately in practice.

  7. 14:30

    Presentation

    The Economics of Cannabis Patient Self-Sufficiency: A Global Perspective

    • Dr Callie Seaman · Managing Director, Sunnyside Consultants

    As cannabis legislation continues to evolve worldwide, countries have adopted a range of regulatory approaches, from strictly controlled medical access to adult-use legalisation. Several jurisdictions have also introduced provisions for patients to cultivate their own cannabis or access it through designated growers, offering alternative models of patient self-sufficiency.

    Read more

    This session will explore these international approaches and examine the broader economic implications of patient self-sufficiency. Moving beyond the direct financial benefits to patients, Dr Callie Seaman will consider the potential impacts on healthcare expenditure, public finances, law enforcement, local communities and the wider economy.

    Drawing on international examples and emerging UK research, the presentation will explore the opportunities, challenges and regulatory considerations associated with patient cultivation and designated growing models, opening a balanced, evidence-led discussion about their potential relevance to future UK cannabis policy.

Included: 12 months' free MCCS membership — worth up to £120

Secure your place — checkout is handled securely via Eventbrite.

Book tickets

Included: 12 months' free MCCS membership — worth up to £120

Enter your email to continue to checkout for Cannabis Health Symposium: London.

Speakers

Call for speakers

Are you a clinician, researcher or specialist who’d like to present? We’re inviting speaker applications for the programme — tell us about your session.

Partners

Partner with us

Interested in sponsoring or partnering with the Cannabis Health Symposium? Register your interest and our team will be in touch about the opportunities.

Final Release£284.09incl. fees

Book tickets

Enter your email to continue to checkout for Cannabis Health Symposium: London.

HCP concession£100for healthcare professionals

Concession tickets

Concession tickets are for healthcare professionals and are available by application. Apply below — once we’ve verified your details we’ll email you a booking link.

Every ticket: CPD certified · 12 months' free MCCS membership, worth up to £120